Regeneron Pharmaceuticals company profile
Company profile
Regeneron Pharmaceuticals has 15,410 employees and is headquartered in Tarrytown, United States.
Its product line begins with EYLEA injections, used for wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinopathy of prematurity. The company also offers Dupixent for atopic dermatitis and asthma, Libtayo for metastatic or locally advanced cutaneous squamous cell carcinoma, Praluent for heterozygous familial hypercholesterolemia and Kevzara for rheumatoid arthritis. Its development work extends to cancer, hematologic conditions and rare diseases, and its partners include Bayer on EYLEA, Alnylam on RNA interference therapeutics, Intellia on CRISPR/Cas9 gene editing and Sanofi on long-acting immunology antibodies. Its medicines are marketed worldwide.
In the fiscal year ended December 2025, revenue reached 14.3 billion US dollars, a 1.0% increase on the previous year, and net income was 4.5 billion US dollars. The company employs 15,410 people and is headquartered in Tarrytown, New York. It was incorporated in 1988.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 777 Old Saw Mill River Road, 10591-6707, Tarrytown
- Employees
- 15,410
- Chief executive
- Leonard Schleifer
- Founded
- 1988
- Fiscal year
- January - December
- Listing
- REGN · NASDAQ
- Indices
- Nasdaq 100S&P 500
- Currency
- USD
- ISIN
- US75886F1075
- Website
- regeneron.com
Regeneron Pharmaceuticals and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| Regeneron PharmaceuticalsREGN | United States | $98.52B | 15,410 | 30.4% | 21.1 |
| ModernaMRNA | United States | $87.1B | 4,700 | -80.8% | — |
| Vertex PharmaceuticalsVRTX | United States | $135.44B | 6,400 | 37.8% | 34.4 |
| argenxARGX | United States | $59.8B | 1,863 | 31.9% | 32.9 |
| BeOne MedicinesONC | United States | $46.98B | 12,000 | 17.8% | 52.7 |
| Royalty PharmaRPRX | United States | $39.4B | 100 | 64.4% | 45.4 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
